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Blocking CCL5-CXCL4 
heteromerization preserves 
heart function after myocardial 
infarction by attenuating leukocyte 
recruitment and NETosis
Tanja Vajen1, Rory R. Koenen  1,2, Isabella Werner3, Mareike Staudt3, Delia Projahn2,3, 
Adelina Curaj3,4,5, Tolga Taha Sönmez3,6,7, Sakine Simsekyilmaz3, David Schumacher3, 
Julia Möllmann3,9, Tilman M. Hackeng1, Philipp von Hundelshausen2,8, Christian Weber1,2,8 & 
Elisa A. Liehn  3,9,10
Myocardial infarction (MI) is a major cause of death in Western countries and finding new strategies 
for its prevention and treatment is thus of high priority. In a previous study, we have demonstrated 
a pathophysiologic relevance for the heterophilic interaction of CCL5 and CXCL4 in the progression 
of atherosclerosis. A specifically designed compound (MKEY) to block this CCL5-CXCR4 interaction is 
investigated as a potential therapeutic in a model of myocardial ischemia/reperfusion (I/R) damage. 
8 week-old male C57BL/6 mice were intravenously treated with MKEY or scrambled control (sMKEY) 
from 1 day before, until up to 7 days after I/R. By using echocardiography and intraventricular pressure 
measurements, MKEY treatment resulted in a significant decrease in infarction size and preserved heart 
function as compared to sMKEY-treated animals. Moreover, MKEY treatment significantly reduced 
the inflammatory reaction following I/R, as revealed by specific staining for neutrophils and monocyte/
macrophages. Interestingly, MKEY treatment led to a significant reduction of citrullinated histone 3 
in the infarcted tissue, showing that MKEY can prevent neutrophil extracellular trap formation in vivo. 
Disrupting chemokine heterodimers during myocardial I/R might have clinical benefits, preserving the 
therapeutic benefit of blocking specific chemokines, and in addition, reducing the inflammatory side 
effects maintaining normal immune defence.
Myocardial infarction (MI) is among the most common causes of death in developed countries. The acute lack of 
blood supply following the blockage of the atherosclerotic coronary vessels induces the death of cardiomyocytes 
and causes a dramatic up-regulation of many inflammatory factors. Effective treatment of acute MI by reperfu-
sion therapy promotes the restoration of blood flow to the ischemic myocardium. However, the ensuing inflam-
matory reactions continue to damage the heart tissue during reperfusion, which may lead to further irreversible 
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cardiomyocyte death. On the other hand, the inflammatory reaction also serves to prepare the myocardial tissue 
and its resident cells for repair1. For example, neutrophils were recently shown to polarize macrophages towards 
a reparative phenotype2, indicating an ambivalent role of neutrophil in MI-related inflammation. Eventually, 
reparative mechanisms lead to the replacement of the injured area with scar tissue3–5.
Despite the discovery of the cardioprotective effects of the innate adaptive responses evoked by different con-
ditioning strategies (pre-, post- and remote conditioning) and intense research to identify key cellular mech-
anisms and drug targets6,7, the currently available treatment for myocardial ischemia/reperfusion (I/R) injury 
is still suboptimal to modulate the phases and actors of post-MI inflammation in order to sufficiently decrease 
subsequent scar size3. This warrants a continued quest for new therapeutic cardioprotective strategies to control 
the inflammatory reaction of myocardial I/R injury.
Chemokines are small cytokines that bind to specific G protein-coupled receptors (GPCR) and exert distinct 
functions, e.g. regulating the activation of leukocytes and coordinating their trafficking to the sites of inflam-
mation8. The benefits of the antagonism of the chemokine system have been demonstrated in various studies 
employing animal models of myocardial infarction3,9–13. However, direct inhibition or genetic deficiency of 
chemokines or their receptors may also be accompanied with immunologic side effects, e.g. impaired immune 
defense against viral and bacterial pathogens or increased autoimmune organ injury14–17. The chemokines CCL5 
(RANTES) and CXCL4 (platelet factor 4) are stored in the secretory α-granules of platelets and were shown 
to be potent neutrophil and monocyte attractants10,18. In addition, these chemokines were shown to undergo 
heterophilic interactions and the CCL5/CXCL4 heteromers are particularly potent in recruiting monocytes and 
neutrophils19–22. Besides leukocyte recruitment, the CCL5/CXCL4 complex was also identified to induce the 
release of neutrophil extracellular traps (NETs) from neutrophils, upon physical contact with platelets23. A cyclic 
peptide, termed MKEY that specifically blocked the heterophilic interaction between CCL5 and CXCL4 could 
prevent the enhancement of CCL5-induced leukocyte recruitment by CXCL420,21 as well as the release of NETs. 
Moreover, administration of MKEY in mice attenuated vascular remodeling processes e.g. atherosclerosis and 
aortic aneurysm and LPS- and ventilator-induced lung injury20,21,23,24. Of note, the disruption of CCL5/CXCL4 
heteromerization did not interfere with systemic immune responses, nor with T cell proliferation or clearance of 
viral infection20. In addition, the MKEY peptide did not have any effects in mice lacking either CCL5 or CXCL4.
Since experimental inhibition of CCL5 showed cardioprotective effects during myocardial reperfu-
sion12,25,26 and the formation of NETs is also associated with its pathophysiology27, we hypothesize that blocking 
CCL5-CXCL4 interactions will have therapeutic benefits in the early phase of MI, with potential impact on injury 
progression and healing after I/R injury. In this study, we evaluated the effects of MKEY treatment on myocardial 
tissue and cardiac function in a mouse model of myocardial I/R.
Results
Effects of MKEY on cardiomyocyte survival and early infarction area. In a previous report, we 
performed pharmacokinetic studies, showing that the plasma half-life of MKEY is 3.02 hours, enough to ensure 
effective plasma concentrations of peptide inhibitor for at least 12 hours. For long-term experiments (up to 7 
days), continuous intravenous infusion was accomplished using osmotic minipumps connected to a jugular vein 
catheter, while intraperitoneal injections were used for short-term experiments (Suppl. Fig. 1). One day after 
reperfusion, the effect of MKEY on cardiomyocyte survival was determined by tetrazolium staining. Evans-blue 
perfusion showed no differences in area at risk (AAR) between the mice treated with MKEY or control sMKEY 
(MKEY: 39.5 ± 2.5% vs. control: 36.8 ± 2.9%, n = 6, Fig. 1A). Tetrazolium staining showed a significant preserva-
tion of viable area in MKEY treated group, compared with control (MKEY: 11.2 ± 2.4% vs. control: 27.3 ± 2.7%, 
p ≤ 0.01, n = 6, Fig. 1B,C). Staining of apoptotic cells (TUNEL) confirmed these results, since the number of 
apoptotic cells were significantly lower in MKEY, compared with control treated mice (MKEY: 4.2 ± 0.6% n = 8, 
vs. control: 16.9 ± 2.1, p ≤ 0.001, n = 9, Fig. 1D–F). These cells were identified as cardiomyocytes by double stain-
ing with α-actinin and TUNEL.
Effects of MKEY treatment on heart function after I/R. To examine the effects of MKEY in heal-
ing following I/R, 8 week-old male mice were treated with MKEY or sMKEY to block specific CCL5-CXCR4 
interactions. Functional parameters of the heart were evaluated by echocardiography after myocardial I/R or 
sham operation (Fig. 1A and Suppl. Videos 1–3). Before MI, no significant differences were observed among the 
groups. After I/R, MKEY treatment preserved the ejection fraction, as compared to sMKEY control mice (Table 1 
and Fig. 2B). Analysis of cardiac output showed compensation in all groups, at similar heart rates (Table 1 and 
Fig. 2C). Moreover, despite unchanged heart weight (Table 1), the hearts treated with MKEY did not dilate after 
ventricular remodelling compared with control hearts, as measured by left ventricular diameter in systole (Table 1 
and Fig. 2D) and diastole (Table 1).
Similar results were obtained by invasive intraventricular measurements using small-animal pressure trans-
ducer catheters, one week after myocardial I/R. Treatment with MKEY preserved the left ventricular developed 
pressure both in the absence or presence of dobutamine (Table 2 and Fig. 2E), whereas heart rates did not differ 
among groups (Table 2). The maximal (dP/dtmax) and minimal (dP/dtmin) pressure change in left ventricle meas-
urements confirmed these results. Moreover, treatment with MKEY preserved contraction (dP/dtmax, Table 2 and 
Fig. 2F) as well as the response to dobutamine stimulation (white bars, Table 2 and Fig. 2F). The compounds had 
no effect on the differential blood pressure, which did not differ between the groups with or without dobutamine 
treatment (Suppl. Fig. 2).
Analysis of remodelling and the inflammatory reaction after MKEY treatment. In accord-
ance with the functional data one week after I/R, mice treated with MKEY showed a significant decrease in the 
size of the infarcted area as compared to control peptide sMKEY-treated animals (8.2 ± 0.9% vs. 12.6 ± 1.5%, 
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respectively, p < 0.05, n = 10, Fig. 3A), with significantly reduced collagen deposition (19.5 ± 1.3% vs. 34.7 ± 2.1%, 
respectively, p < 0.0001, n = 10, Fig. 3B). Analysis of neo-angiogenesis in the infarcted area revealed no significant 
differences in the level of CD31-positive capillaries between the groups (37.2 ± 9.5 vessels/mm2 in MKEY-treated 
Figure 1. Analysis of infarcted area after MKEY treatment. Area at risk (AAR) as % total area (A) and infarcted 
area as % of AAR (B) were determined by Evans-blue perfusion and tetrazolium staining 1d after injury in control 
and MKEY-treated mice. (C) Representative heart sections from both groups are shown. *p < 0.05 vs. control 
(n = 6); (D) Quantification of the number of apoptotic cells as determined by TUNEL staining in MKEY- and 
control-treated mice. *p < 0.05 vs. control (n = 8); (E,F) Representative images of TUNEL staining of infarct tissue. 
Scale bar 50 µm. (E) TUNEL-positive cells are green, inset: control staining. (F) TUNEL-positive cells are red and 
cardiomyocytes are visualised using α-actinin (green). Nuclei were stained using DAPI (blue).
Sham (n = 10) Control (n = 10) MKEY (n = 10) P value (ANOVA)
Ejection Fraction (%) 69.9 ± 2.56 45.1 ± 3.86 65.4 ± 2.59 <0.0001
Cardiac Output (ml/min) 16.7 ± 0.86 11.3 ± 2.13 12.9 ± 2.29 <0.0001
LVEDD (mm) 3.66 ± 0.09 4.09 ± 0.17 3.47 ± 0.57 0.0189
LVESD (mm) 2.14 ± 0.09 3.12 ± 0.19 2.26 ± 0.15 0.0001
Heart rate (bpm) 409 ± 11 382 ± 16 386 ± 12 ns
Heart weight (mg) 120 ± 7 113 ± 7 112 ± 5 ns
Table 1. Echocardiography parameters. LVEDD: left ventricular end-diastolic diameter; LVESD: left 
ventricular end-systolic diameter; ns: no significance.
www.nature.com/scientificreports/
4SCIENTIFIC REPORTS |  (2018) 8:10647  | DOI:10.1038/s41598-018-29026-0
vs. 28.2 ± 7.8 vessels/mm2 in control mice, Fig. 3C). Moreover, we have previously shown that platelet-derived 
CCL5 and CXCL4 mediate monocyte and neutrophil recruitment. Here, CCL5 and CXCL4 release from plate-
lets following TRAP-6 stimulation significantly increased neutrophil recruitment to immobilized platelets, 
and co-incubation with MKEY significantly reduced neutrophil recruitment (MKEY: 170.8 ± 12.0 vs. control 
229.3 ± 6.3 neutrophils/mm2, n = 3–6, p < 0.05, Fig. 4A). We next analysed the recruitment of inflammatory 
cells in the infarcted area one day after myocardial I/R. Monocyte/macrophage infiltration was also reduced in 
Figure 2. Effects of MKEY treatment on heart function after I/R. Representative images of echocardiography 
(A) and quantification of ejection fraction (B) cardiac output (C) and preserved systolic (D) ventricular 
dimensions in MKEY-treated, compared to sMKEY-treated control mice, one week after I/R. Left ventricular 
developed pressure (E) and contraction (F) as well as the response to dobutamine stimulation (white bars 
E,F), were assessed using intraventricular Millar catheter. #p < 0.05 vs. sham; *p < 0.05 vs. control; §p < 0.05 vs. 
unstimulated (n = 10).
Sham (n = 10) Control (n = 10) MKEY (n = 10) P value 
(*control)Basal Dobutamine Basal Dobutamine Basal Dobutamine
Developed Pressure (mmHg) 94.9 ± 6.38 145.5 ± 12.21 70.1 ± 3.68 91.3 ± 4.32 96.9 ± 8.65* 127 ± 11.1 <0.05
dPdt max (mmHg/s) 6357 ± 624 13569 ± 713 3138 ± 232 7093 ± 755 4911 ± 440* 11480 ± 644 <0.05
dPdt min (mmHg/s) −4595 ± 667 −7795 ± 461 −2850 ± 181 −5121 ± 616 −4302 ± 425* −6611 ± 285 <0.05
Heart rate (bpm) 235 ± 17 414 ± 30 223 ± 11 387 ± 19 221 ± 10 425 ± 22 ns
Table 2. Intraventricular pressure measurements. dP/dtmax: the increase in left ventricle pressure change as 
measure of contraction; dP/dtmin: the decrease in left ventricle pressure change as measure of relaxation; ns: no 
significance.
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the infarcted areas after MKEY treatment, as revealed by F4/80 staining, one day after I/R (107 ± 17.9 mono-
cytes/mm2 vs. 203 ± 28.6 monocytes/mm2 in control group, n = 8, p < 0.05, Fig. 4B). Consistent with our in vitro 
observations, MKEY treatment significantly decreased post-ischemic neutrophil infiltration, as shown by specific 
esterase staining (MKEY: 144 ± 26.2 vs. control: 460 ± 128 neutrophils/mm2, n = 8, p < 0.05, Fig. 4B). However, 
the lymphocyte infiltration did not differ between the studied groups (Suppl. Fig. 2). Recent work has demon-
strated involvement of NETs in the pathophysiology of myocardial infarction27. Incubation of neutrophils with 
LPS- or TRAP6-treated platelets, but not with LPS- or TRAP6 alone, led to a robust formation of NETs, which 
could be inhibited by the administration of MKEY (Suppl. Fig. 3), thereby confirming previous observations23. 
Interestingly, MKEY treatment almost completely abrogated the formation of neutrophil extracellular traps com-
pared to control as reflected by the strongly reduced number of citrullinated histone 3 (H3cit) -positive cells in the 
infarcted tissue (MKEY: 21.7 ± 12.4 vs control 748.0 ± 72.0 cells/mm2, n = 3, p < 0.01, Fig. 4D).
Discussion
In this study, we have demonstrated the efficiency of a synthetic peptide, MKEY, designed to specifically block 
CCL5-CXCL4 interactions, in the treatment of myocardial ischemia/reperfusion injury. Administration of MKEY 
significantly reduced infarction size due to a reduction of inflammation after MI. After treatment with MKEY, 
neutrophil and monocyte infiltration into the affected myocardial areas was reduced, which positively affected 
the infarction outcome and heart function. Previous studies have shown that circulating monocytes infiltrate the 
affected tissue in distinct waves after myocardial infarction, with classical Ly6Chi CCR2+ monocytes being respon-
sible for clearance of dead cells and the Ly6Chi CCR2− monocytes for tissue repair4,28. In addition, under healthy 
steady-state conditions the cardiac tissue is populated with resident macrophages. Recent studies have shown 
that tissue resident macrophages originate to a considerable part from embryonic yolk-sac-derived precursors, at 
least in the heart, liver and brain29. Under homeostatic conditions, the heart was found to be mainly populated by 
resident yolk-sac-derived macrophages Ly6Clow CCR2− cells that are self-maintained by local proliferation29 and 
these can be replaced or replenished during cardiac inflammation by circulating Ly6Chi CCR2+ cells. Although 
the roles of the chemokine receptors CCR2 and CCR5, as well as CX3CR1 on the influx of circulating monocytes 
into inflamed tissues has been well characterized28,30, the effects of the individual chemokines on resident mac-
rophages is less well defined. The classical Ly6Chi CCR2+ monocytes have been shown to use the CCL5 receptors 
CCR1 and −5 to enter the inflamed atherosclerotic aorta31. However, the role of CCL5 on the behaviour of resi-
dent macrophages is currently not known. Yet in a previous study implementing MKEY in a model of ischemic 
stroke, a strong inhibition of immigrated monocytes by MKEY could be observed, whereas the resident (yolk 
sac-derived) microglia were not affected by MKEY treatment32. In the present study, we also observed a decrease 
of cardiac monocyte content after treatment with MKEY. We have not been able to distinguish between resident 
and infiltrated cells, since the Ly6Clow CCR2− monocytes accumulate in the infarcted area later after the acute 
hypoxic event (peaking after 7 days)28. Thus, in combination with the previous findings by Fan and colleagues32, 
we postulate that during the early phase after MI (after 1 day), MKEY mostly affects the inflammatory Ly6Chi 
CCR2+ monocytes. Due to the particular distribution of the infarcted area through the heart, characteristic for 
ischemia/reperfusion injury, a significant decrease in infarction size after MKEY treatment allows the remote 
myocardium to compensate the lost tissue and thereby to preserve the regional contractility and heart func-
tion (Tables 1 and 2). The myocardium has a complex cellular structure, which besides cardiomyocytes includes 
fibroblasts and endothelial cells integrated in capillaries. During hypoxia, endothelial cells reorganize and start 
Figure 3. Analysis of remodeling after MKEY treatment. Infarction size (A) collagen deposition (B) and 
CD31+ collateral vessel formation (C) in MKEY- and control sMKEY-treated mice one week after I/R. *p < 0.05 
vs. control (n = 10); Scale bar 50 µm.
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angiogenesis governed by angiogenic factors released directly after MI, e.g. VEGF or CXCL1233, while fibroblasts 
start to proliferate34. The cardiomyocytes however are undergoing apoptosis or even necrosis, as indicated by the 
findings in our study. However, unlike shown for blockade of CCL535, angiogenesis was not affected, indicating 
that this side effect does not accompany MKEY treatment. In various interventional approaches, the diverse 
aspects of chemokine biology were addressed from different angles, particularly for CCL5, e.g. receptor-ligand 
interactions, prevention of the chemokine-glycosaminoglycan interaction, interfering with the receptor signalling 
or trafficking pathways, and prevention of heterodimer formation36, with varying success37,38.
Of all chemokines, the CC-chemokine receptors CCR1 and CCR5 and their ligand CCL5 appear to play a 
particular role in cardiovascular diseases. While low serum levels of CCL5 were associated with disease progres-
sion in atherosclerosis39, plasma levels of CCL5 were significantly elevated in patients with refractory ischemic 
symptoms versus stabilized patients40. By binding to its receptors, CCL5 mediates the arrest and transmigration 
of monocytes and T lymphocytes through the endothelium. However, it appears that CCL5 receptors exerted 
differential functions in induction and progression of cardiovascular diseases41. While CCR5 showed a protective 
role in atherosclerosis by a mechanism involving interleukin-10, CCR1 supported inflammation and neointima 
formation after vascular injury42,43. In contrast, deletion of CCR1 was shown to reduce tissue injury and preserve 
Figure 4. Analysis of inflammatory reaction after MKEY treatment. Human neutrophil recruitment to human 
platelets immobilized on collagen-coated glass slides under flow conditions (1 dyne/cm2), without or with 
TRAP-6 activation (50 µM) in presense of sMKEY (control) or MKEY (A) p = 0.001 (n = 3–6), monocyte/
macrophage infiltration ((B) F4/80 staining), neutrophil infiltration ((C) specific esterase staining), and NET 
formation ((D) H3cit staining), in MKEY- and sMKEY-treated mice, one day after I/R; *p < 0.05 vs. control 
(n = 8); Scale bar 50 µm.
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left ventricular function after myocardial infarction in mice10, whereas deletion of CCR5 enhanced inflammation, 
impaired recruitment of regulatory T cells and induced more severe cardiac dilation44. However, the administra-
tion of CCL5 antagonists or blocking antibodies could prevent both; the progression of atherosclerotic lesions 
by impairing the chemokine oligomerization45,46 and myocardial injury after infarction, by reducing leukocyte 
infiltration, chemokine expression and apoptosis in the affected myocardium12,25. Despite the evident beneficial 
effect of CCL5 antagonism in experimental studies, CCL5 blockade in clinical practice does not appear to be 
feasible, due to a potential compromise of the systemic immune response, delayed macrophage-mediated viral 
clearance and impaired normal T cell functions47,48. Local administration would be an alternative to prevent such 
side effects. For example, intramyocardial injection of CCL5 antagonists in combination with a protease-resistant 
form of the stem cell attractant CXCL12, embedded in biodegradable hydrogels led to reduction of tissue damage 
and to an improvement of cardiac function26. However, the clinical applicability of this approach needs to be 
established. Targeting the heteromerization of CCL5 with CXCL4 appears to be a realistic alternative approach to 
attenuate its functions without affecting the systemic immune response38. This notion is supported by the results 
in this study, which reveal that the inhibition of heteromer formation by MKEY reduced myocardial damage 
and neutrophil and monocyte infiltration into the affected tissue to a similar extent as full inhibition with CCL5 
antagonists or blocking antibodies12,25.
Whereas the functions and the antagonism of CCL5 in myocardial infarction have been extensively stud-
ied, less is known about the role of CXCL4. CXCL4 is released from alpha-granules of activated platelets dur-
ing platelet aggregation, and may modulate blood coagulation by binding to heparin-like molecules. Although 
first described as a chemoattractant for neutrophils and monocytes49, later studies have ascribed some of these 
CXCL4 activities to contaminations of other chemokines50. In fact, CXCL4 has been recognized as a physiological 
inhibitor of megakaryocytopoiesis and angiogenesis, rather than a classical leukocyte-recruiting chemokine51. 
Still, CXCL4 might promote inflammation, notably in cardiovascular disease. For example, genetic deletion of 
CXCL4 reduced atherosclerotic plaque and neointima formation in mice52,53. A recent study demonstrated that 
CXCL4 acts as a pro-inflammatory and mitogenic factor on smooth muscle cells, promoting remodelling after 
vascular injury54. During acute coronary syndrome, serum levels of CXCL4 increase in patients55, correlating with 
the severity of the myocardial injury56. On a mechanistic level, the enhancement of CCL5-function by CXCL4 
appeared to be largely mediated by CCR1 requiring its third extracellular loop57, consistent with the role of CCR1 
in myocardial ischemia/reperfusion injury10. Thus, CXCL4 appears to play an auxiliary role in CCL5-mediated 
CCR1 activation, a function that might be of crucial importance for the in vivo activity of CCL5. This notion is 
also supported by recent studies that implemented MKEY in mouse models of inflammatory disease. For exam-
ple, MKEY was shown to suppresses abdominal aortic aneurysm formation and progression, reducing aortic 
diameter enlargement, preserving medial elastin fibres and smooth muscle cells, and attenuating mural mac-
rophage infiltration, angiogenesis, and aortic metalloproteinase 2 and 9 expression24. It is known that cardiomyo-
cytes express CCL5 and that the addition of CCL5 to cardiomyocytes significantly reduced myocyte contractility 
such as after MI, with no alterations in the Ca2+ transition58. Since the chemokines CCL5 and CXCL4 exert 
specific functions by heteromerization, blocking this by MKEY should not change the levels of these chemokines, 
yet it does block the function of the heteromers. Administration of MKEY reduced the infiltration of monocytes 
into ischemic brain tissue in a mouse model of stroke32. Nevertheless, it cannot be excluded that MKEY also has 
direct effects on cardiomyocytes. However, possible effects of CCL5 and CXCL4 on cardiomyocytes and their 
modulation by MKEY are subject to future investigation.
The contribution of platelets to reperfusion injury by promoting inflammatory reactions within the ischemic 
myocardium has been demonstrated in several earlier studies59,60. Particulary, platelet-neutrophil interac-
tions provoke post-reperfusion cardiac dysfunction. MKEY treatment significantly decreased the adhesion of 
PMN to immobilized TRAP-6 stimulated platelets under flow conditions. Moreover, MKEY interfered with 
platelet-neutrophil interactions in an aseptic and a septic mouse model of acute lung injury, diminishing neu-
trophil lung extravasation, oedema formation and neutrophil elastase release21. In addition, the administration 
of MKEY decreased the severity of ventilator-induced lung injury in mice23. Interestingly, CCL5 and CXCL4 
were found to induce NET release by neutrophils and MKEY could effectively prevent NET formation when 
neutrophils were pre-incubated with platelets. These findings were corroborated by our observations showing 
that NET-release induced by TRAP-6- or LPS-activated platelets could be attenuated by the addition of MKEY. 
In a previous study implementing a mouse model of myocardial I/R, the administration of the NET-degrading 
enzyme DNAseI led to a reduction of infarct size and to an improvement of ejection fraction27, indicating that 
ischemic myocardial I/R damage is driven by NET formation. When myocardial I/R was performed in mice 
deficient for peptidylarginine deiminase 4 (PAD4), having neutrophils defective in NET-formation, infarct size 
was significantly reduced27.
Although our study takes a different approach, blocking CCL5/CXCL4 interactions by a peptide inhibitor, we 
could also link the observed reduction in myocardial I/R damage after administration of MKEY with a reduction 
of neutrophil infiltration and an associated decrease in NET formation.
A limitation of this study is the administration of the MKEY peptide before the experimental induction of 
myocardial I/R, thereby affecting clinical translation of our findings. Since this study was primarily conceived 
to investigate mechanistic aspects of the CCL5/CXCL4 complex in myocardial I/R, we have opted to pre-treat 
the animals with the inhibitory compound before coronary occlusion to achieve plasma levels of the com-
pounds at the moment of treatment. Due to this pre-administration of the compounds, the observed reduction 
in infarct sizes might be due to an attenuation of inflammation before the induction of ischemia, resulting in less 
post-infarction damage and scar formation. Nevertheless, results from our model experiments and from previous 
work of others have demonstrated direct effects of the MKEY peptide on leukocyte recruitment and behaviour, 
both affecting the inflammatory response after ischemia. Thus, we can conclude that disruption of the CCL5/
CXCL4 complex does attenuate the post-ischemic inflammatory reaction. Although infusion of the compound 
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before the induction of ischemia might hamper clinical applicability, the data still demonstrate that our approach 
can in principle present a useful strategy for reducing tissue damage.
In conclusion, the peptide MKEY might represent a new therapeutic approach for the treatment of athero-
sclerosis and myocardial infarction. This strategy could have potential clinical impact, having advantage over 
direct antagonism of chemokines or their receptors, by preserving the therapeutic effect of specifically blocking 
chemokines, yet also reducing the side effects and maintaining normal immune defence.
Material and Methods
Ethics. Studies on human subjects involved blood sampling for platelet and neutrophil isolation and were 
performed conform the declaration of Helsinki and approval was granted by the local institutional ethics boards 
(Ethikkommission bei der Medizinischen Fakultät der LMU München, and the medisch-ethische toetsingscom-
missie (METC) at Maastricht University). All animal experiments and study protocols were performed at the 
University Hospital of the RWTH Aachen and approved by local authorities, complying with German animal pro-
tection laws and performed according to the guidelines from Directive 2010/63/EU of the European Parliament 
(ethics approval granted by Landesamt für Natur- und Verbaucherschutz (LANUV) Nordrhein-Westfalen 
(NRW) Nrs. 50.203.2-AC 37, 26/05 and 84-02.04.2013.A185).
Animal Treatment. C57BL/6 mice (11–12 per group) were treated with MKEY or scrambled control MKEY 
(sMKEY) (Suppl. Fig. 1), synthesized by t-Boc-based solid-phase peptide synthesis as described20. For infarction 
size and functional parameter analysis, MKEY or sMKEY was dissolved at 2.27 mg/ml (1 mmol/l) in 0.01% for-
mic acid and loaded in 100 µl Alzet type 1007D osmotic pumps (0.5 µl/hour, Charles River, Cologne, Germany), 
resulting in a dose of 1.3 mg/kg i.v per 24 hours. One day before I/R, the mice were anesthetized by ketamine and 
xylazine (100 and 10 mg/kg i.p., respectively) and the pumps were implanted for intravenous delivery into the 
jugular vein, according to manufacturer’s instructions. One week after I/R, the mice underwent echocardiography 
and intraventricular pressure measurements. Finally, one day or one week after I/R, the mice were anesthetized 
with an intraperitoneal injection of ketamine and xylazine (100 mg/kg and 10 mg/kg, respectively) and hearts 
were excised, fixed in formalin and embedded in paraffin for further analysis.
To avoid supplementary burden of animals according to the new European animal experimental regulations, 
mice undergoing analysis after short period of time (24 hours) were treated one day before and on day of I/R 
intraperitoneally with 9 mg/kg MKEY and 9 mg/kg sMKEY as described20,21 (Suppl. Fig. 1).
Myocardial ischemia and reperfusion. 11–12 week-old male mice were intubated under general anes-
thesia (100 mg/kg ketamine, 10 mg/kg xylazine, i.p.) and positive-pressure ventilated with oxygen and 0.2% iso-
flurane using a rodent respirator61. Hearts were exposed by left thoracotomy and MI was produced by suture 
occlusion of the left anterior descending artery (LAD) over a silicone tube. After 60 min of ischemia, the tube 
and suture were removed to permit reperfusion. Sham-operated mice (10 per group) underwent all surgical 
actions except LAD occlusion. The muscle layer and skin incision were closed with a silk suture. Either one day 
or one week after I/R, the hearts were harvested for further analysis. The mice received buprenorphine (0.1 mg/
kg) as analgesia before and for up to 5 days after surgery. Surgery was accompanied by moderate lethality in mice, 
with approximately 20% of the animals dying within 24 hours, no differences were observed between the treated 
groups.
Echocardiography. Two-dimensional and M-mode echocardiographic measurements were performed on 
a small-animal ultrasound imager (Vevo 770, FUJIFILM Visualsonics, Toronto, Canada). Both procedures were 
performed before and after I/R. Mice were anesthetized by mask with 1.5% isoflurane and placed in supine posi-
tion on a warming pad. The ejection fraction, cardiac output, left ventricular end-diastolic (LVEDD), left ven-
tricular end-systolic (LVESD) diameters, heart rate and heart weight were recorded and analysed26.
In vivo assessment of cardiac function. One week after I/R (Suppl. Fig. 1), the mice were anesthetized 
with ketamine/xylazine as above and a Millar Mikro-Tip® Pressure Transducer Catheter (Millar Instruments, 
Houston, Tx) was introduced into the right common carotid artery. After ligation, the catheter was slowly 
advanced into the left ventricle, and blood pressure in the left ventricle, as well as increase (dP/dtmax) and 
decrease (dP/dtmin) in left ventricular pressure were measured.
Evans-blue/tetrazolium staining. AAR and infarction size were also measured one day after reperfusion 
(Suppl. Fig. 1). The hearts were excised from mice treated with MKEY and sMKEY (8 per group) and washed with 
PBS, the ligature over the LAD was renewed and 200 µl Evans-blue was perfused through the aorta. After freezing 
at −20 °C for one hour, the hearts were cut in 5 slices, and incubated in tetrazolium solution at 37 °C for 10 min, 
followed by 10% formaldehyde for 10 min. The slices were fixed between microscopic slides for photography and 
measurements. The total ventricle area, the blue-stained normally perfused area, red-stained injured but still 
viable area and white infarcted area were measured using ImageJ. AAR was calculated as the difference between 
the total and blue-stained area and express as percent from total ventricle area. Infarction size was calculated as 
white unstained area and expressed as percent of AAR61. Of the initial 8 animals per group, 6 were taken into the 
analysis (1 of each group died after surgery, 1 sample per group was lost during pre-analytical processing).
Histology and immunohistochemistry. To evaluate MI size, serial sections (10–12 sections per mouse, 
400 µm apart, up to the mitral valve) were stained with Gomori’s 1-step trichrome stain. The infarcted area was 
determined for all sections using Diskus software (Hilgers, Königswinter, Germany) and expressed as a percent-
age of total left ventricular volume. Blue-stained collagen content was analyzed with Cell P Software (Olympus, 
Hamburg, Germany) and expressed as a percentage of the infarcted area. Serial sections (3 sections per mouse, 
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400 µm apart) were stained to analyse the infarcted area for neutrophil content (specific esterase, Sigma, St. 
Louis, MO), neutrophil extracellular trap formation (H3cit, abcam 5103, Cambridge, UK), macrophage content 
(F4/80), lymphocytes (CD3, both Serotec, Oxford, UK) apoptotic cells (TUNEL, MEBSTAIN apoptosis kit II, 
MBL, Woburn, MA, USA) and CD31-positive capillaries (Santa Cruz, Santa Cruz, CA). Positive-stained cells or 
vessels were counted in six different fields per section and expressed as cells or vessels per mm2.
In vitro NET formation. Human neutrophils were isolated from the blood of healthy donors, after obtaining 
informed consent as described previously62,63. Isolated neutrophils were resuspended at (4 × 105) in RPMI 1640 
medium with 1% fetal calf serum. Citrate-anticoagulated whole blood was obtained from healthy donors and 
platelets were isolated as previously described64. Neutrophils (2 × 105) were seeded on poly-L-lysine coated glass 
coverslips and incubated with platelets (1 × 107) pretreated with lipopolysaccharide (LPS; 5 µg/mL) or throm-
bin receptor activator peptide (TRAP; 50 µM) with or without MKEY (10 µM) for 30 minutes at 37 °C. After 
30 minutes of further incubation, samples were fixed with 2% PFA for 10 minutes at 37 °C, washed with PBS and 
incubated with Syto13® green fluorescent nucleic acid stain (1 µM) for 20 minutes. Images were obtained with a 
fluorescence microscope (DM2000; Leica, Wetzlar, Germany).
Neutrophil adhesion under flow. Platelets were isolated from citrate-anticoagulated whole blood of healthy vol-
unteers as described previously64 and resuspended at a concentration of 2 × 107/mL. Washed platelets were immo-
bilized on soluble rat-tail collagen-treated (30 µg/mL) glass cover slips (Menzel, 24 × 60 mm, #1.5) for 1.5 hours 
at 37 °C in a moisture chamber. Nonspecific binding was blocked with 0.5% human serum albumin (HSA) in 
HEPES buffer for 30 min at 37 °C. A confluent layer of spread platelets was formed, which was examined by phase 
contrast microscopy (EVOS-FL) before and after flow perfusion and was not affected by flow shear stress. Human 
neutrophils were isolated from the blood of healthy donors, after obtaining informed consent as described 
above. Isolated neutrophils were resuspended at (1 × 106) in HBSS with 10 mM HEPES (pH 7.4) and 0.2% HSA 
(HHHSA buffer) and labeled with 1 µM Syto-13 (Thermofisher Scientific, Waltham, MA). Platelets were activated 
with 50 µM TRAP-6 in presence or absence of MKEY or sMKEY (1 µg/mL) for 1 h at 37 °C. Platelet-coated glass 
cover slips were assembled in parallel flow chambers (0.4 mm Luer sticky slides, ibidi®, Martinsried, Germany) 
and then mounted in a fluorescent microscope (EVOS-FL) using a 10x objective and a CCD camera. Prior to 
neutrophil perfusion, 2 mM MgCl2 and 3 mM CaCl2 was added into the cell suspensions and perfused for 2 min 
at a shear stress of 1 dynes/cm2. Following 2 min of perfusion, the number of firmly adherent cells per mm2 (no 
movement for >10 s) was counted in 6 different fields within 5 min.
Statistical analysis. Data represent mean ± SEM. Statistical analysis was performed with Prism 4 software 
(GraphPad). Means of two groups were compared with unpaired Student-t test and of more than two groups 
with 1-way ANOVA followed by Newman-Keuls post-hoc-test, as indicated. P-values of < 0.05 were considered 
significant.
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